GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (FRA:ONMA) » Definitions » Cyclically Adjusted PB Ratio

OncoSec Medical (FRA:ONMA) Cyclically Adjusted PB Ratio : 0.00 (As of Oct. 31, 2024)


View and export this data going back to 2015. Start your Free Trial

What is OncoSec Medical Cyclically Adjusted PB Ratio?

As of today (2024-10-31), OncoSec Medical's current share price is €0.14. OncoSec Medical's Cyclically Adjusted Book per Share for the quarter that ended in Jan. 2023 was €211.58. OncoSec Medical's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for OncoSec Medical's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:ONMA's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.62
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

OncoSec Medical's adjusted book value per share data for the three months ended in Jan. 2023 was €-1.713. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €211.58 for the trailing ten years ended in Jan. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


OncoSec Medical Cyclically Adjusted PB Ratio Historical Data

The historical data trend for OncoSec Medical's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical Cyclically Adjusted PB Ratio Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.31 0.22 0.41 0.20 0.06

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.07 0.06 0.04 0.01

Competitive Comparison of OncoSec Medical's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, OncoSec Medical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoSec Medical's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's Cyclically Adjusted PB Ratio falls into.



OncoSec Medical Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

OncoSec Medical's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.14/211.58
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoSec Medical's Cyclically Adjusted Book per Share for the quarter that ended in Jan. 2023 is calculated as:

For example, OncoSec Medical's adjusted Book Value per Share data for the three months ended in Jan. 2023 was:

Adj_Book=Book Value per Share/CPI of Jan. 2023 (Change)*Current CPI (Jan. 2023)
=-1.713/126.2230*126.2230
=-1.713

Current CPI (Jan. 2023) = 126.2230.

OncoSec Medical Quarterly Data

Book Value per Share CPI Adj_Book
201304 182.829 98.107 235.224
201307 135.011 98.557 172.911
201310 286.892 98.536 367.506
201401 320.745 98.692 410.221
201404 361.294 100.023 455.930
201407 505.971 100.520 635.347
201410 491.259 100.176 618.996
201501 478.867 98.604 613.001
201504 426.095 99.824 538.780
201507 441.161 100.691 553.027
201510 359.837 100.346 452.629
201601 341.366 99.957 431.066
201604 273.956 100.947 342.552
201607 309.685 101.524 385.028
201610 241.114 101.988 298.409
201701 206.455 102.456 254.346
201704 154.781 103.167 189.371
201707 94.372 103.278 115.339
201710 85.615 104.070 103.840
201801 90.789 104.578 109.580
201804 112.994 105.708 134.923
201807 80.677 106.324 95.776
201810 80.818 106.695 95.610
201901 73.571 106.200 87.442
201904 58.310 107.818 68.264
201907 44.809 108.250 52.249
201910 28.482 108.577 33.111
202001 5.854 108.841 6.789
202004 19.291 108.173 22.510
202007 11.515 109.318 13.296
202010 10.959 109.861 12.591
202101 23.828 110.364 27.252
202104 22.433 112.673 25.131
202107 18.100 115.183 19.835
202110 13.921 116.696 15.058
202201 9.793 118.619 10.421
202204 7.188 121.978 7.438
202207 3.360 125.002 3.393
202210 -0.558 125.734 -0.560
202301 -1.713 126.223 -1.713

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


OncoSec Medical  (FRA:ONMA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


OncoSec Medical Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoSec Medical Business Description

Traded in Other Exchanges
N/A
Address
24 North Main Street, Pennington, NJ, USA, 08534
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

OncoSec Medical Headlines

No Headlines